Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy

被引：1
|
作者：
Yang, J. C-H. [1 ]
Ramalingam, S. S. [2 ]
Kim, T. M. [3 ]
Kim, S-W. [4 ]
Riely, G. J. [5 ]
Mekhail, T. [6 ]
Nguyen, D. [7 ]
Campelo, M. R. Garcia [8 ]
Felip, E. [9 ]
Bazhenova, L. [10 ]
Jin, S. [11 ,12 ]
Griffin, C. [13 ]
Bunn, V. [12 ,14 ]
Lin, J. [12 ,15 ]
Churchill, E. N. [12 ,16 ]
Mehta, M. [11 ,12 ]
Janne, P. A. [17 ]
Zhou, C. [18 ]
机构：
[1] Natl Taiwan Univ, Ctr Canc, Dept Med Oncol, Taipei, Taiwan
[2] Emory Univ, Winship Canc Inst, Hematol & Med Oncol Dept, Atlanta, GA USA
[3] Seoul Natl Univ Hosp, Dept Hematooncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[5] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[6] AdventHlth Orlando, Thorac Canc Program, Orlando, FL USA
[7] Pacific Shores Med Grp, Hematol Oncol, Long Beach, CA USA
[8] Univ Hosp A Coruna, CHUAC, Dept Med Oncol, La Coruna, Spain
[9] Vall Hebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
[10] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[11] Millennium Pharmaceut Inc, Clin Sci, Oncol, Cambridge, MA USA
[12] Takeda Pharmaceut Co Ltd, Cambridge, MA USA
[13] Millennium Pharmaceut Inc, Global Patient Safety Evaluat, Cambridge, MA USA
[14] Millennium Pharmaceut Inc, Stat, Cambridge, MA USA
[15] Millennium Pharmaceut Inc, Oncol Stat, Cambridge, MA USA
[16] Millennium Pharmaceut Inc, Global Med Affairs Oncol, Cambridge, MA USA
[17] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[18] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1836
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1231P
引用
收藏
页码：S975 / S975
页数：1
相关论文
共 50 条
  • [41] Real-world frequency of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations by site of insertion
    Viteri, S.
    Bauml, J. M.
    Bazhenova, L.
    Ou, S-H. I.
    Girard, N.
    Schaffer, M.
    Rose, J.
    Curtin, J.
    Karkera, J.
    Mahadevia, P.
    Minchom, A. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S699 - S699
  • [42] Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
    Illini, Oliver
    Saalfeld, Felix Carl
    Christopoulos, Petros
    Duruisseaux, Michael
    Vikstroem, Anders
    Peled, Nir
    Demedts, Ingel
    Dudnik, Elizabeth
    Eisert, Anna
    Hashemi, Sayed M. S.
    Janzic, Urska
    Kian, Waleed
    Mohorcic, Katja
    Mohammed, Saara
    Silvoniemi, Maria
    Rothschild, Sacha I.
    Schulz, Christian
    Wesseler, Claas
    Addeo, Alfredo
    Armster, Karin
    Itchins, Malinda
    Ivanovic, Marija
    Kauffmann-Guerrero, Diego
    Koivunen, Jussi
    Kuon, Jonas
    Pavlakis, Nick
    Piet, Berber
    Sebastian, Martin
    Velthaus-Rusik, Janna-Lisa
    Wannesson, Luciano
    Wiesweg, Marcel
    Wurm, Robert
    Albers-Leischner, Corinna
    Aust, Daniela E.
    Janning, Melanie
    Fabikan, Hannah
    Herold, Sylvia
    Klimova, Anna
    Loges, Sonja
    Sharapova, Yana
    Schuetz, Maret
    Weinlinger, Christoph
    Valipour, Arschang
    Overbeck, Tobias Raphael
    Griesinger, Frank
    Jakopovic, Marko
    Hochmair, Maximilian J.
    Wermke, Martin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [43] PRACTICAL GUIDE FOR INFUSION-RELATED REACTION (IRR) MANAGEMENT WITH AMIVANTAMAB FOR EXON 20 INSERTION MUTATION (EX20INS) NON-SMALL CELL LUNG CANCER (NSCLC): A NURSE'S VIEW
    Dougherty, Lindsay
    Bhaumik, Amitabha
    D'Andrea, Denise
    Johnson, Andy
    ONCOLOGY NURSING FORUM, 2022, 49 (02) : 20 - 21
  • [44] A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
    Yoh, Kiyotaka
    Azuma, Koichi
    Hayashi, Hidetoshi
    Nishio, Makoto
    Chikamori, Kenichi
    Ichihara, Eiki
    Watanabe, Yasutaka
    Asato, Takayuki
    Kitagawa, Tadayuki
    Fram, Robert J.
    Ohe, Yuichiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (10) : 1461 - 1474
  • [45] Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
    Illini, O.
    Saalfeld, F. C.
    Christopoulos, P.
    Duruisseaux, M.
    Vikstrom, A.
    Peled, N.
    Demedts, I.
    Dudnik, E.
    Eisert, A.
    Hashemi, S. Ms
    Janzic, U.
    Kian, W.
    Mohorcic, K.
    Mohammed, S.
    Silvoniemi, M.
    Rothschild, S. I.
    Schulz, C.
    Wesseler, C.
    Addeo, A.
    Armster, K.
    Itchins, M.
    Ivanovic, M.
    Kauffmann-Guerrero, D.
    Koivunen, J.
    Kuon, J.
    Pavlakis, N.
    Piet, B.
    Sebastian, M.
    Velthaus-Rusik, J. -L.
    Wannesson, L.
    Wiesweg, M.
    Wurm, R.
    Albers-Leischner, C.
    Aust, D. E.
    Janning, M.
    Fabikan, H.
    Herold, S.
    Klimova, A.
    Loges, S.
    Sharapova, Y.
    Schuetz, M.
    Weinlinger, C.
    Lang-Stoeberl, A.
    Valipour, A.
    Overbeck, T. R.
    Griesinger, F.
    Jakopovic, M.
    Hochmair, M. J.
    Wermke, M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 : S534 - S535
  • [46] Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
    Liu, Geoffrey
    Nyaw, Shi Feng
    Mok, Tony S. K.
    Curcio, Hubert
    Cortot, Alexis B.
    Kam, Tsz Yeung
    Descourt, Renaud
    Chik, Yin Kwan
    Cheema, Parneet
    Gwinnutt, James M.
    Churchill, Eric N.
    Nyborn, Justin
    Curran, Eileen
    Savell, Alexandra
    Yin, Yu
    Chong, Katie
    Tanaka-Chambers, Yuka
    Kretz, Julian
    Cadranel, Jacques
    CANCER MEDICINE, 2025, 14 (03):
  • [47] Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis
    Girard, N.
    Park, K.
    Viteri, S.
    Schioppa, C. A.
    Diels, J.
    Oguz, M.
    Rodrigues, B. H.
    Rahhali, N.
    Sermon, J.
    Ghilotti, F.
    Li, T.
    Knoblauch, R. E.
    Mahadevia, P.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S38 - S38
  • [48] Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)
    Sabari, J.
    Kim, T. M.
    Spira, A.
    Lee, S. H.
    Chang, G. C.
    Shih, J. -Y.
    Hochmair, M. J.
    Schioppa, C. A.
    Schioppa, C. A.
    Panaccione, A.
    Rose, J. B.
    Chioda, M.
    Mahadevia, P.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E23 - E23
  • [49] Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)
    Kim, T. M.
    Lee, S-H.
    Chang, G-C.
    Shih, J-Y.
    Hochmair, M. J.
    Sabari, J. K.
    Spira, A. I.
    Schioppa, C. A.
    Rose, J. B.
    Chioda, M.
    Panaccione, A.
    Mahadevia, P.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S48 - S48
  • [50] MATCHING-ADJUSTED INDIRECT COMPARISON OF AMIVANTAMAB VS. MOBOCERTINIB IN EGFR EXON 20 INSERTION-MUTATED NON-SMALL CELL LUNG CANCER
    Van Sanden, S.
    Rahhali, N.
    Schioppa, C.
    Diels, J.
    Rodrigues, B.
    Chandler, C.
    Kapetanakis, V
    Jain, R.
    Li, T.
    VALUE IN HEALTH, 2022, 25 (07) : S526 - S526
12345